Bristol Myers Squibb Reports Phase 3 CheckMate-025 Results for Opdivo in Renal Cell Carcinoma

Bristol Myers Squibb today announced results from the Phase 3 CheckMate-025 trial evaluating Opdivo (nivolumab) versus everolimus in patients with previously treated advanced renal cell carcinoma. The trial met its primary endpoint, demonstrating a significant improvement in overall survival with Opdivo. These results led to FDA approval of Opdivo for previously treated advanced RCC.